BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TomoTherapy Announces Pricing of Initial Public Offering


5/9/2007 10:00:59 AM

MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (Nasdaq:TTPY - News) announced today the pricing of its initial public offering of 11,743,420 shares of common stock at a price per share of $19.00, of which 10,602,960 shares are being sold by TomoTherapy Inc. and 1,140,460 shares are being sold by certain selling stockholders. TomoTherapy Inc. expects to receive net proceeds from the offering of approximately $185 million. The shares will be listed on the Nasdaq National Market and will trade under the symbol "TTPY" beginning May 9, 2007. The closing of the offering is scheduled to take place on May 14, 2007. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,761,513 shares of common stock at the initial public offering price to cover over-allotments, if any.

Merrill Lynch & Co. acted as sole-bookrunning manager, Piper Jaffray & Co. acted as co-lead manager, and Thomas Weisel Partners LLC, Robert W. Baird & Co. Incorporated and William Blair & Company acted as co-managers for the offering. The offering will be made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the Hi Art® system, an advanced and versatile radiation therapy system for the treatment of a wide variety of cancers. Hi Art® and the TomoTherapy logo are registered trademarks of TomoTherapy Incorporated.

Contact: TomoTherapy Incorporated Patty Kitowski Marketing Communications Manager 608.824.2820 pkitowski@tomotherapy.com

Source: TomoTherapy Incorporated

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES